Aptamer-conjugated nanoparticles for cancer cell detection.

Aptamer-conjugated nanoparticles (ACNPs) have been used for a variety of applications, particularly dual nanoparticles for magnetic extraction and fluorescent labeling. In this type of assay, silica-coated magnetic and fluorophore-doped silica nanoparticles are conjugated to highly selective aptamers to detect and extract targeted cells in a variety of matrixes. However, considerable improvements are required in order to increase the selectivity and sensitivity of this two-particle assay to be useful in a clinical setting. To accomplish this, several parameters were investigated, including nanoparticle size, conjugation chemistry, use of multiple aptamer sequences on the nanoparticles, and use of multiple nanoparticles with different aptamer sequences. After identifying the best-performing elements, the improvements made to this assay's conditional parameters were combined to illustrate the overall enhanced sensitivity and selectivity of the two-particle assay using an innovative multiple aptamer approach, signifying a critical feature in the advancement of this technique.

[1]  Bertrand Tavitian,et al.  Nucleic acid aptamers in cancer medicine , 2002, FEBS letters.

[2]  J. M. Henry,et al.  Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[4]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[5]  D. Shangguan,et al.  Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.

[6]  Hongyu Zhao,et al.  Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Joshua E. Smith,et al.  Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. , 2007, Analytical chemistry.

[8]  H. Ragde,et al.  Presentation of prostate tumor antigens by dendritic cells stimulates T‐cell proliferation and cytotoxicity , 1996, The Prostate.

[9]  A. Heimberger,et al.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients , 2009, Expert opinion on biological therapy.

[10]  Weihong Tan,et al.  Molecular aptamer beacons for real-time protein recognition. , 2002, Biochemical and biophysical research communications.

[11]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[12]  Kemin Wang,et al.  Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.

[13]  Ying Li,et al.  Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. , 2007, Clinical chemistry.

[14]  K. Hoang-Xuan,et al.  Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.

[15]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[16]  Weihong Tan,et al.  Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. , 2006, Analytical chemistry.

[17]  Xiaohong Fang,et al.  Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. , 2010, Accounts of chemical research.

[18]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[19]  L. Gold,et al.  Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.